Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia

Am J Hematol. 2021 Apr 1;96(4):E114-E117. doi: 10.1002/ajh.26105. Epub 2021 Feb 26.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Dexamethasone / administration & dosage
  • Dexamethasone / adverse effects
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Female
  • Hematologic Diseases / chemically induced
  • Humans
  • Hypocalcemia / chemically induced
  • Hyponatremia / chemically induced
  • Male
  • Middle Aged
  • Neoplasm, Residual
  • Oligopeptides / administration & dosage
  • Oligopeptides / adverse effects
  • Peripheral Nervous System Diseases / chemically induced
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Rituximab / administration & dosage
  • Treatment Outcome
  • Vincristine / administration & dosage
  • Vincristine / adverse effects
  • Young Adult

Substances

  • Oligopeptides
  • Rituximab
  • Vincristine
  • carfilzomib
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide

Supplementary concepts

  • CVAD protocol